News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,027 Results
Type
Article (14169)
Company Profile (282)
Press Release (251576)
Section
Business (79492)
Career Advice (153)
Deals (13225)
Drug Delivery (35)
Drug Development (50429)
Employer Resources (31)
FDA (5712)
Job Trends (5127)
News (144360)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21633)
ALS (59)
Alzheimer's disease (817)
Antibody-drug conjugate (ADC) (81)
Approvals (5720)
Artificial intelligence (104)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (137)
Cancer (1223)
Cardiovascular disease (98)
Career advice (132)
Career pathing (2)
CAR-T (106)
Cell therapy (301)
Cervical cancer (6)
Clinical research (40788)
Collaboration (487)
Compensation (215)
Complete response letters (13)
COVID-19 (1031)
CRISPR (36)
C-suite (134)
Cystic fibrosis (75)
Data (1273)
Denatured (11)
Depression (28)
Diabetes (120)
Diagnostics (1289)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (76)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (75)
Earnings (29532)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (47993)
Executive appointments (396)
FDA (6300)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (452)
Gene editing (86)
Generative AI (9)
Gene therapy (224)
GLP-1 (350)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6586)
Huntington's disease (21)
IgA nephropathy (19)
Immunology and inflammation (77)
Indications (18)
Infectious disease (1089)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (17)
Intellectual property (53)
Interviews (17)
IPO (7262)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (199)
Leadership (2)
Legal (1385)
Liver cancer (30)
Lung cancer (175)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (111)
MASH (46)
Medical device (2586)
Medtech (2587)
Mergers & acquisitions (6242)
Metabolic disorders (354)
Multiple sclerosis (49)
NASH (13)
Neurodegenerative disease (54)
Neuropsychiatric disorders (22)
Neuroscience (1172)
NextGen: Class of 2025 (2016)
Non-profit (852)
Northern California (1477)
Now hiring (21)
Obesity (183)
Opinion (100)
Ovarian cancer (54)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (100)
Partnered (6)
Patents (104)
Patient recruitment (63)
Peanut (35)
People (25465)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14402)
Phase II (18977)
Phase III (11995)
Pipeline (627)
Podcasts (45)
Policy (34)
Postmarket research (852)
Preclinical (6030)
Press Release (30)
Prostate cancer (51)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (267)
Real estate (1414)
Recruiting (12)
Regulatory (8519)
Reports (14)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (86)
Series B (56)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1320)
Special edition (11)
Spinal muscular atrophy (116)
Sponsored (11)
Startups (1970)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11715)
Vaccines (200)
Venture capitalists (28)
Webinars (7)
Weight loss (103)
Women's health (15)
Worklife (2)
Date
Last 7 days (353)
Last 30 days (1561)
Last 365 days (20022)
2025 (4201)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16224)
2018 (11740)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (51)
Arkansas (5)
Asia (17174)
Australia (2911)
California (3393)
Canada (1033)
China (303)
Colorado (127)
Connecticut (141)
Delaware (85)
Europe (36958)
Florida (396)
Georgia (103)
Idaho (16)
Illinois (206)
India (7)
Indiana (84)
Iowa (1)
Japan (66)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (437)
Massachusetts (2684)
Michigan (69)
Minnesota (132)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (849)
New Mexico (12)
New York (936)
North Carolina (510)
North Dakota (4)
Northern California (1477)
Ohio (105)
Oklahoma (9)
Oregon (21)
Pennsylvania (646)
Puerto Rico (3)
Rhode Island (14)
South America (208)
South Carolina (3)
Southern California (1320)
Tennessee (25)
Texas (382)
Utah (48)
Virginia (66)
Washington D.C. (28)
Washington State (314)
Wisconsin (13)
266,027 Results for "melinta therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
October 17, 2024
·
3 min read
Press Releases
Melinta Joins NHIA Future of Infusion Advisory Council
December 2, 2024
·
3 min read
Drug Development
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris.
May 23, 2024
·
4 min read
Pharm Country
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.
February 23, 2024
·
12 min read
Business
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial.
December 5, 2023
·
8 min read
Pharm Country
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)
Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).
October 2, 2023
·
5 min read
Pharm Country
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
Melinta Therapeutics, LLC announced today, the presentation of nine scientific presentations with data from its current anti-infective portfolio at Infectious Disease Week (IDWeek) 2023, taking place October 11-15, 2023, in Boston, MA.
October 11, 2023
·
3 min read
Pharm Country
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc., announced that they have entered into a License Agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
November 9, 2023
·
13 min read
Pharm Country
Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
Melinta Therapeutics, LLC today announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
July 31, 2023
·
4 min read
Business
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin) and VABOMERE ® (meropenem and vaborbactam), four novel anti-infective products.
May 15, 2023
·
3 min read
1 of 26,603
Next
